Dawn Halkuff, serving as a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), sold 20,000 shares of the company's common stock on June 4, 2026. The transaction resulted in a total value of $121,885. The shares were sold at prices ranging from $5.960 to $6.170. This sale was executed under a Rule 10b5-1 trading plan that Halkuff adopted on September 4, 2025. The stock currently trades at $6.18, down 21% year-to-date but up 39% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels, with a Fair Value estimate above the trading price.
On the same day, Halkuff also acquired 24,193 shares of common stock through a restricted stock unit grant. These shares, which represent a contingent right to receive common stock, were granted under the company's 2018 Stock Option and Incentive Plan. They are set to vest upon the earlier of June 4, 2026, or the date of the company's next annual meeting of stockholders, subject to continued service.
Additionally, Halkuff received a grant of 32,996 stock options, also under the Plan, with an exercise price of $6.15 per share. These options are exercisable until June 4, 2036, and will vest under similar conditions as the restricted stock units.
Following these transactions, Halkuff directly holds 119,193 shares of Xeris Biopharma common stock and 32,996 stock options. An additional 5,410 shares of common stock are held indirectly through the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017, though Halkuff disclaims beneficial ownership of these shares except to the extent of her pecuniary interest. For deeper insights into Xeris Biopharma's financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.
In other recent news, Xeris Biopharma reported robust financial results for the first quarter of 2026, with total revenue increasing by 38% year-over-year to $83.1 million. Although the revenue slightly missed forecasts, the company exceeded earnings expectations with an earnings per share (EPS) of $0.01. This development marks a positive achievement for the company in surpassing EPS projections. Additionally, notable analyst firms have been closely monitoring these results, though specific upgrades or downgrades were not mentioned in the recent reports. These developments highlight the company's financial performance and its reception among investors.